Clinical trial · Expanded Access
TETRAVI Expanded Access Program
Expanded Access Use of Multivirus-Specific Cytotoxic T-Lymphocytes for Pediatric Patients With EBV, CMV, Adenovirus, or BK Virus Infections Post Allogeneic Stem Cell Transplant
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 16, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260916-000001
Summary
Brief summary (as posted)
This Expanded Access Program (EAP) allows qualified physicians within Texas to obtain access to multivirus-specific cytotoxic T lymphocytes (VSTs) developed under Baylor College of Medicine's TETRAVI program (NCT04013802) for the treatment of persistent or recurrent infections with EBV, CMV, adenovirus, or BK virus in pediatric patients being treated in Texas who have received allogeneic stem cell transplants and have no other suitable therapeutic options.
Conditions
Conditions (7)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenovirus Infection | — | UNRESOLVED | — |
| BK Virus Infection | — | UNRESOLVED | — |
| Cytomegalovirus Infections | — | UNRESOLVED | — |
| Epstein-Barr Virus Infection | — | UNRESOLVED | — |
| JC Virus Infection | — | UNRESOLVED | — |
| Post-Allogeneic Stem Cell Transplant Complications | — | UNRESOLVED | — |
| Viral Infections Post-Transplant | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| HLA-matched VSTs (Multivirus-specific Cytotoxic T Lymphocytes) | Biological | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 17 Years
Show eligibility criteria text
Inclusion Criteria: * Patients \<18 years of age. * Patients who have undergone myeloablative or non-myeloablative allogeneic HSCT or CAR T therapy in the Sate of Texas (USA). * Have persistent, increasing, or recurrent infections with EBV, CMV, adenovirus, or BK virus despite standard treatment. * Treating physician must be based in Texas. * Must obtain IRB approval and submit a protocol to FDA with Letter of Authorization from Baylor. Exclusion Criteria: * Patients with active uncontrolled infections unrelated to the viruses mentioned. * Use of certain immunosuppressive agents within 28 days. * Serious uncontrolled medical conditions or relapse of underlying disease.
References
Publications (0)
Data not yet available